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Background The impact of neuraminidase inhibitors (NAIs) on
influenza-related pneumonia (IRP) is not established. Our objective
was to investigate the association between NAI treatment and IRP
incidence and outcomes in patients hospitalised with A(H1N1)
pdm09 virus infection.
Methods A worldwide meta-analysis of individual participant data
from 20 634 hospitalised patients with laboratory-confirmed A
(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613)
‘pandemic influenza’. The primary outcome was radiologically
confirmed IRP. Odds ratios (OR) were estimated using generalised
linear mixed modelling, adjusting for NAI treatment propensity,
antibiotics and corticosteroids.
Results Of 20 634 included participants, 5978 (290%) had IRP;
conversely, 3349 (162%) had confirmed the absence of radiographic
pneumonia (the comparator). Early NAI treatment (within 2 days
of symptom onset) versus no NAI was not significantly associated
with IRP [adj. OR 083 (95% CI 064–106; P = 0136)]. Among the
5978 patients with IRP, early NAI treatment versus none did not
impact on mortality [adj. OR = 072 (044–117; P = 0180)] or
likelihood of requiring ventilatory support [adj. OR = 117 (071–
192; P = 0537)], but early treatment versus later significantly
reduced mortality [adj. OR = 070 (055–088; P = 0003)] and
likelihood of requiring ventilatory support [adj. OR = 068 (054–
085; P = 0001)].
Conclusions Early NAI treatment of patients hospitalised with A
(H1N1)pdm09 virus infection versus no treatment did not reduce
the likelihood of IRP. However, in patients who developed IRP,
early NAI treatment versus later reduced the likelihood of mortality
and needing ventilatory support.
Keywords Hospitalisation, individual participant data meta-ana-
lyses, influenza-related pneumonia, neuraminidase inhibitors.
Please cite this paper as: Muthuri et al. (2016) Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant
data meta-analysis. Influenza and Other Respiratory Viruses 10(3), 192–204.
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Introduction
Influenza-related pneumonia (IRP) was a common and
severe complication during the 2009–2010 influenza pan-
demic.1–5 Neuraminidase inhibitors (NAIs), primarily oselta-
mivir and zanamivir, were widely recommended for patients
with suspected or confirmed influenza A(H1N1)pdm09 virus
infection.6,7 However, prior to the 2009–2010 pandemic,
evidence of their effectiveness in seasonal influenza, while
strong for modest symptom alleviation, was less robust for
reductions in pneumonia incidence or improvements in
pneumonia outcome.8–10 The findings from meta-analyses
have been inconsistent. One study based on observational
data from 150 660 patients with mainly seasonal influenza
suggested no statistically significant reduced likelihood of
pneumonia.9 Another used clinical trials data from 4452
community adult patients with uncomplicated seasonal
influenza and concluded that oseltamivir significantly
reduced ‘self-reported, investigator-mediated, unverified
pneumonia’ by 45%, compared with placebo, but data on
radiologically confirmed pneumonia were not available.11
A recent individual participant data (IPD) analysis of
clinical trial data investigating the efficacy of oseltamivir
when compared to placebo in patients with seasonal
influenza reported a reduction in risk of pneumonia by
60%.12 Individual observational studies during the 2009–
2010 pandemic suggest a possible benefit of NAIs in reducing
pneumonia incidence, but are limited by small sample
sizes.13–16 A meta-analysis of 2009–2010 pandemic data from
patients hospitalised with influenza A(H1N1)pdm09 virus
infection reported that early treatment with NAIs reduced
the likelihood of IRP compared to late treatment by 65%.17
But this work encountered high degrees of heterogeneity and
inconsistent or incomplete adjustment for potential con-
founders.
We present a global meta-analysis based on IPD, control-
ling for potential confounders and treatment propensity. We
investigate the association between NAI treatment and
radiologically confirmed IRP in patients hospitalised with
A(H1N1)pdm09 virus infection, and outcomes including
admission to intensive care units (ICUs), ventilatory support,
acute respiratory distress syndrome (ARDS) and mortality in
patients with IRP.
Some of these results have been previously reported in the
form of an abstract.18
Methodology
The PRIDE research consortium
Details of the Post-pandemic Review of anti-Influenza Drug
Effectiveness (PRIDE) study have been published previ-
ously.19 Briefly, participating research centres were identified
during the conduct of a systematic review of published
studies on the same topic.17 Additional centres were
recruited through this network of global collaborators,
publicity at conferences and by word of mouth. Centres that
fulfilled the minimum data set requirements (Table S2) were
eligible for inclusion in the consortium. In total, 79 research
groups from 38 countries and six World Health Organization
(WHO) regions contributed data on 143 786 patients with
laboratory- or clinically diagnosed influenza A(H1N1)pdm09
virus infection (Figure 1). No data were provided or funded
for collection by pharmaceutical companies. The protocol
was registered with the PROSPERO register of systematic
reviews, number CRD42011001273.20
Data standardisation, exposure and outcome
variables
Data were standardised using a common data dictionary19
before pooling for analysis. For this analysis, the primary
outcome was IRP defined as laboratory-confirmed or clin-
ically diagnosed influenza A(H1N1)pdm09 virus infection
plus pneumonia confirmed by chest radiography, occurring
at any time after the onset of influenza-like illness. For
radiographic evidence of pneumonia, we accepted:
1. A formal chest radiograph or computerised tomograph
report documenting ‘pneumonia’.
2. Data sets reporting pneumonia and chest radiograph as
discrete variables, in which both items were marked
positive or ‘yes’.
3. Formal chest radiograph reports of one or more abnor-
malities consistent with pneumonia: pulmonary infil-
trates, lobar consolidation, homogeneous segmental
consolidation with or without cavitation, diffuse bilateral
interstitial and/or interstitial–alveolar (mixed) infiltrates,
segmental consolidation, lobar consolidation, rounded
pneumonia, bronchopneumonia, interstitial pneumonia,
pneumatoceles, acute pulmonary infiltrates, as previously
validated by Bewick et al. and Franquet,21,22 unless a
formal radiograph report also stated ‘no pneumonia’.
4. Chest radiograph report not provided, but specific
mention in the clinical case notes that a radiograph had
been formally reported as showing pneumonia.
The absence of IRP (‘no IRP’) was defined as laboratory-
confirmed or clinically diagnosed influenza A(H1N1)pdm09
infection plus a radiographic report that did not identify
abnormalities consistent with pneumonia, or which stated
that pneumonia was ‘not present’ (irrespective of any specific
features reported).
Comparative exposure to NAI treatment was defined as
follows: early NAI treatment (≤2 days after symptom onset)
versus no NAI treatment; early NAI treatment versus later
NAI treatment (treatment commenced >2 days after symp-
tom onset); later NAI treatment versus no NAI treatment;
and NAI treatment (irrespective of timing) versus no NAI
treatment.
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Propensity scoring
Propensity scores for the likelihood of NAI treatment were
calculated for each patient within individual data sets using
multivariable logistic regression for each of the three NAI
exposure measures, using covariates as described by Muthuri
et al.19 (Table S3). Subsequently, propensity scores were
categorised into quintiles for each individual data set.
Statistical analysis
To investigate the association between the use of NAI
treatment and IRP, we compared patients with IRP against
those with no IRP. We used generalised linear mixed
modelling to conduct separate analyses for each NAI
exposure comparison using the xtmelogit command in STATA
(version 13; StataCorp LP, College Station, TX, USA).
Individual studies were included in the model as a random
intercept in order to account for differences in baseline
outcome. Adjustment was performed for propensity of NAI
treatment, antibiotics administered during hospitalisation
and corticosteroids administered during hospitalisation.
Missing data in the covariates were included as a separate
dummy category to allow for comparisons across the crude
and adjusted analyses. We excluded data sets in which all
patients (n = 1352 from 14 data sets) were diagnosed with
IRP. Stratified analyses were conducted for adults
(≥16 years), children (<16 years; including <5- and 5- to
15-year subgroups), pregnant women, laboratory-confirmed
A(H1N1)pdm09 cases and patients admitted to critical care
units. We did not include patients with unknown pneumonia
status (n = 3615 across 21 data sets) in this analysis.
401 corresponding authors contacted
35 169 in patients* from 77 centres 
325 centres excluded 
273 centres did not respond 
52 declined to participate 
3 centres identified by contact 
with experts 
168 048 potentially eligible patients 
disclosed by 79 centres 
24 260 patients without influenza 
AH1N1pdm09 virus infection
143 786 patients with laboratory 
confirmed or clinically diagnosed 
influenza A H1N1pdm09 virus infection 
108 617 excluded 
2543 unknown admission status 
106 012 outpatients 
62 outpatients with onset of 
illness before March 1, 2009 
(Mexico)
5657 patients with missing data for 
exposure to neuraminidase inhibitors 
were excluded
20 634 patients from 69 centres included in 
analysis 
9327 with radiological information on 
pneumonia status
7692 with clinical information on 
pneumonia status
3615 with unknown pneumonia status
8 datasets (n = 8878 patients) which did 
not provide data on pneumonia status
were excluded
57 patients excluded
47 overlapping data
1 inpatient with onset of illness 
before March 1, 2009 (Mexico)
9 missing data for key variables
Figure 1. Study flow diagram. *Two hundred
and sixty patients added since publication of
Muthuri et al.17 following clarification of
inpatient status from data collaborator.
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In the subgroup of patients with IRP, we further examined
the effect of NAI treatment on secondary clinical outcomes:
admission to ICUs, ventilatory support, ARDS and mortality.
At this juncture, we re-included the 14 data sets in which all
patients were diagnosed with IRP.
Sensitivity analysis
In some clinical settings, chest radiography is not routinely
performed for hospitalised patients with influenza unless a
pulmonary complication is also suspected; therefore, reliance
on radiographic abnormalities is likely to give a conservative
estimate of pneumonia incidence. Accordingly, we also
performed a sensitivity analysis, which considered a diagno-
sis of ‘any pneumonia’ by combining IRP with physician-
diagnosed pneumonia (PDP), the latter defined as labora-
tory-confirmed or clinically diagnosed influenza A(H1N1)
pdm09 plus a physician diagnosis of pneumonia, but where
no chest radiograph report was available. For this analysis,
patients categorised as ‘no pneumonia’ had laboratory-
confirmed or clinically diagnosed influenza A(H1N1)pdm09
with no evidence of IRP on chest radiography; unknown
pneumonia status; or, in the absence of a chest radiograph
report, no documented clinical record of PDP, recognising
that clinicians record positive findings in the case record, but
not all negative findings.
Results are presented as unadjusted and adjusted odds
ratios (OR) with 95% confidence intervals (95% CI), and
two-sided P-values < 005 were considered statistically sig-
nificant. Statistical analyses were conducted using STATA
(version 13).
Results
Overall, data were obtained on 35 169 individuals hospi-
talised with A(H1N1)pdm09 virus infection (Figure 1). Of
these, 29 512 (84%) patients were admitted from January
2009 through March 2011 (Figure S1) with information
available on NAI treatment. A further eight data sets
comprising 8878 hospitalised patients that did not provide
data on pneumonia status were excluded from the analysis
(Figure 1; Table S4).
Of the 20 634 patients included, 9327 (45%) had a positive
or negative diagnosis of IRP confirmed by chest radiography,
while 7692 (37%) did not have chest radiography, but had a
positive or negative diagnosis of PDP documented. The
remaining 3615 (18%) hospitalised patients had neither
radiological nor clinical documentation of pneumonia status;
they were included in the sensitivity analysis (only) as having
‘no pneumonia’. The characteristics of hospitalised patients
with and without pneumonia included in the pooled data set
are shown in Table 1. Baseline characteristics of each
constituent data set included in the analysis are presented
in Table S5.
Overall, patients with IRP were more likely than patients
with no IRP to be adult (P < 0001), non-pregnant
(P < 0001), free of underlying medical conditions
(P = 0038), be from outside the WHO European region
(P < 0001) and have laboratory-confirmed influenza A
(H1N1)pdm09 infection (P < 0001). They were more likely
to receive NAI treatment (P < 0001), antibiotics
(P < 0001) and corticosteroids (P < 0001), be admitted
to critical care facilities (P < 0001) and require ventilatory
support (<0001) or die (P < 0001) (Table 1).
Association between NAI treatment and IRP
Overall, 63 data sets provided data on 9327 hospitalised
patients with a positive or negative diagnosis of pneumonia
confirmed by chest radiography. After the exclusion of 14
data sets in which all patients had IRP (n = 1352, Table S5),
7975 patients remained in the analysis.
Early NAI (≤2 days) versus no NAI treatment
Early NAI use compared with no NAI use was not
significantly associated with IRP in our overall sample
Figure 2. Summary of main findings for
influenza-related pneumonia (IRP) in
laboratory- and clinical diagnosed influenza
patients, all ages.
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[adjusted OR 083 (95% CI 064–106)], nor when we
considered laboratory-confirmed cases, adults, pregnant
women or children (Table 2 and Figure 2). However, point
estimates for subgroups tended to suggest an OR below
unity, except in ICU patients. When considering ‘any
pneumonia’, we found a borderline significant reduced OR
associated with early NAI use in all patients [adjusted OR
083 (95% CI 070–098)], with further borderline significant
risk reductions also noted among laboratory-confirmed
cases; these findings lost a statistical significance when
further stratified by patient subgroups but the point
estimates remained consistent (Table 2).
For this exposure, we also looked at the impact of
corticosteroids on the association between NAI treatment
and IRP. A test for interaction between NAI treatment and
corticosteroids did not show any significant interaction (P-
value: 0275). Stratified analysis (by corticosteroid use) did
not show any significant association between NAI use and
IRP (Table S9).
Early NAI (≤2 days) versus later NAI (>2 days) treatment
Early NAI treatment compared with later was associated with
significantly lower odds of IRP [adjusted OR, 043 (95% CI,
037–051)] (Table 2 and Figure 2). The odds ratios did not
change substantially when only cases of laboratory-confirmed
influenza were considered (Table 2). Similarly, statistically
significant lower odds of IRP were observed in adults aged
16 years or older, children aged 0–15 years, pregnant women
and among adult patients admitted to critical care. However,
there was no statistically significant association with IRP
among children admitted to critical care (Table 2). The
pattern of these findings in terms of direction and signifi-
cance was similar when considering ‘any pneumonia’
(Table 2).
Later NAI (>2 days) versus no NAI treatment
Neuraminidase inhibitor treatment beyond 2 days of symp-
tom onset compared with no NAI was associated with
statistically significant higher odds of IRP [adjusted OR, 170
(95% CI, 134–217)]. Similar statistically significant associ-
ations were observed among cases of laboratory-confirmed
influenza, adults and critically ill children, but not among all
children, pregnant women and critically ill adults. Likewise,
with ‘any pneumonia’, the direction and statistical signifi-
cance of these findings did not change (Table 2 and Figure 2).
NAI anytime versus no NAI treatment
After adjustment, the likelihood of IRP in patients treated
with NAI (administered at any point after illness onset) was
132 (95% CI 110–159), compared with no NAI treatment
(Table 2 and Figure 2). This OR did not change substantially
when only patients with laboratory-confirmed A(H1N1)
pdm09 were included [adjusted OR 129 (95% CI 106–
157)]. Similarly, we observed significantly higher odds of
IRP associated with NAI antiviral use in adults and
borderline significantly increased odds of IRP in adults
admitted to an ICU. However, there was no significant
association between NAI treatment and IRP in children aged
0–15 years, pregnant women and critically ill children. The
pattern of these findings was not changed by considering ‘any
pneumonia’, except in children admitted to critical care
where we observed statistically significant higher odds of IRP
for patients treated with an NAI (at any time).
Post hoc analyses on non-ICU patients (all ages) are shown
in Table S6; children’s subgroups aged <5 years and 5–15 are
shown in Tables S7 (all severities) and S8 (critically ill).
Impact of NAI treatment on clinical outcomes
among patients with pneumonia
We performed a further analysis, restricted to patients with
IRP (n = 5978) (Table 3), and a sensitivity analysis by
including ‘any pneumonia’ patients (n = 7054). Data sets in
which all patients had IRP (n = 1352 patients, 14 data sets)
were re-added at this juncture.
In the IRP cohort, we did not observe any statistically
significant associations with clinical outcomes when early
NAI treatment was compared with no NAI treatment; but for
‘any pneumonia’, we observed that early NAI treatment
versus no NAI was associated with an increased likelihood of
admission to an ICU [adjusted OR, 181 (95% CI, 127–
258); P = 0001], but a reduced likelihood of mortality [adj.
OR, 062 (95% CI, 040–096); P = 0032].
In patients with IRP, early NAI treatment compared to
later NAI was associated with significantly lower odds of
ventilatory support [adjusted OR, 068 (95% CI, 054–085);
P = 0001] and mortality [adjusted OR, 070 (95% CI, 055–
088); P = 0003]. These effects were similar and remained
statistically significant for ‘any pneumonia’.
Later NAI treatment versus no NAI was significantly
associated with increased likelihood of ICU admission and
ventilatory support. The pattern of these findings in terms of
direction and significance was unchanged when considering
‘any pneumonia’. Likewise, patients with IRP who received
NAI at any time versus no NAI treatment were more likely to
be admitted to an ICU [adj. OR, 159 (95% CI, 121–209),
P = 0001] and receive ventilatory support [adj. OR, 167
(95% CI, 122–229), P = 0001].
Discussion
The strengths of this study include having data on a large
number of patients of all ages hospitalised with influenza A
(H1N1)pdm09 virus infection (mainly laboratory con-
firmed) from different geographical regions worldwide.
Given the practical and ethical constraints likely to be
involved in conducting placebo-controlled trials during
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Table 1. Characteristics of pooled data set of 20 634 patients admitted to hospital with influenza A(H1N1)pdm09 virus infection with and without
pneumonia
Characteristics
Radiologically diagnosed pneumonia
status Radiologically or PDP status
IRP No IRP Any pneumonia* No pneumonia**
Number of patients*** 5978 (1000) 3349 (1000) 7054 (1000) 13 580 (1000)
Number of male cases 3266 (546) 1879 (560) 3811 (540) 6645 (489)
Age: median (IQR) in years 36 (17–52) 26 (14–46) 35 (14–51) 22 (8–38)
Adults (≥16 years) 4560 (763) 2436 (727) 5208 (738) 8482 (625)
Children (<16 years) 1411 (236) 912 (272) 1821 (258) 4966 (366)
Obese† 952 (159) 229 (68) 1072 (152) 744 (55)
Smoking 914 (153) 481 (144) 958 (136) 867 (64)
Pregnant women†† 219 (131) 150 (160) 279/1967 (142) 1153/4397 (262)
WHO regions
African region 28 (05) 1 (003) 31 (04) 10 (01)
Region of the Americas 2314 (387) 550 (164) 2703 (383) 4948 (364)
Eastern Mediterranean region 178 (30) 206 (62) 549 (78) 3086 (227)
European region 2635 (441) 2032 (607) 2932 (416) 4080 (300)
South-East Asia region 45 (08) 86 (26) 45 (06) 157 (12)
Western Pacific region 778 (130) 474 (142) 794 (113) 1299 (96)
A(H1N1)pdm09 diagnosis
Laboratory confirmed 5755 (963) 3146 (939) 6827 (968) 13 194 (972)
Clinically diagnosed 223 (37) 203 (61) 227 (32) 386 (28)
Comorbidities†††
Any comorbidity 3021 (505) 1795 (536) 3531 (501) 5449 (401)
Asthma 856 (143) 777 (227) 968 (137) 1430 (105)
COPD 432 (72) 249 (74) 454 (64) 345 (25)
Other chronic lung disease 492 (82) 525 (157) 648 (92) 1668 (123)
Heart disease 650 (109) 341 (102) 713 (101) 786 (58)
Renal disease 278 (47) 113 (34) 328 (47) 349 (26)
Liver disease 122 (20) 73 (22) 127 (18) 121 (09)
Cerebrovascular disease 121 (20) 122 (36) 133 (19) 170 (13)
Neurological disease 436 (73) 237 (71) 492 (70) 508 (37)
Diabetes 634 (106) 280 (84) 725 (103) 690 (51)
Immunosuppression 525 (88) 242 (72) 610 (87) 852 (63)
H1N1pdm09 vaccination‡ 121/2917 (42) 48/1701 (28) 163/3738 (44) 176/6237 (28)
Time from symptom onset to
hospital admission, days, median (IQR)
4 (2–6) 2 (1–4) 3 (2–6) 2 (1–4)
Time from symptom onset to
antiviral treatment, days, median (IQR)
4 (2–7) 2 (1–4) 4 (2–7) 2 (1–4)
Antiviral agents used
No NAI treatment 582 (97) 540 (161) 724 (103) 4336 (319)
Any NAI 5396 (903) 2809 (839) 6330 (897) 9244 (681)
Oral oseltamivir‡‡ 5356 (993) 2782 (990) 6263 (989) 9068 (981)
Intravenous/inhaled zanamivir‡‡ 134 (25) 40 (14) 155 (25) 158 (17)
Intravenous peramivir‡‡ 42 (08) 5 (02) 42 (07) 7 (01)
NAI (regimen unknown)‡‡ 1 (002) 5 (02) 17 (03) 82 (09)
NAI and non-NAI‡‡ 75 (14) 15 (05) 76 (12) 18 (02)
NAI combination therapy‡‡ 134 (25) 23 (08) 144 (23) 71 (08)
Early NAI (≤2 days of symptom onset)‡‡ 1067 (198) 1057 (376) 1353 (214) 3459 (374)
Later NAI (>2 days after symptom onset)‡‡ 2843 (527) 998 (355) 3362 (531) 3221 (348)
Other in-hospital treatment
Antibiotics 3604 (603) 1731 (517) 4265 (605) 5521 (407)
Corticosteroids 1658 (277) 626 (187) 1709 (242) 1024 (75)
Hospital length of stay, days, median (IQR) 9 (5–17) 5 (3–7) 8 (4–17) 4 (2–7)
Other patient outcomes
Acute respiratory distress syndrome 265 (44) 10 (03) 341 (48) 43 (03)
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pandemic periods, the use of large-scale pooled observational
data offers the best chance of producing meaningful results
on the effect of NAIs on severe outcomes such as pneumonia.
Our definition of IRP, which required radiographic
evidence of pneumonia, represents a conservative estimate
of all cases of pneumonia as radiography was not routinely
performed for every patient in all participating centres. We
therefore also performed separate analyses, which included
patients with PDP. Some patients with PDP would not have
had pneumonia (false positives), and thus, we expect that the
true effect estimates of the association of NAI with
pneumonia and clinical outcomes probably fall somewhere
between the values obtained in the analyses for IRP and ‘any
pneumonia’.
However, there are inevitable limitations, based on the use
of retrospective observational data. Because we found an
increase in IRP in several comparisons where we might have
expected NAIs to have a protective effect, this suggests that
our propensity scoring was not able to fully adjust for the
tendency to use NAIs in more severe disease. We were unable
to fully adjust for severity of illness within each propensity
score because the different severity measures used across
individual data sets were disparate. Furthermore, we
included a broad spectrum of pneumonia severity and the
available data did not permit stratification according to
pneumonia severity (e.g. using CURB65 or the Pneumonia
Severity Index).
NAI treatment and occurrence of pneumonia
Our findings that early initiation of NAI treatment
(≤48 hours after illness onset) compared with later was
associated with a significant reduction in IRP and ‘any
pneumonia’ corroborate those previously reported from
observational data on hospitalised influenza patients.9,17,19
These trends were consistently observed across multiple
subgroups: laboratory-confirmed influenza, adults, children,
pregnant women and adults requiring critical care (but not
children). For early treatment versus none, highly consistent,
protective point estimates were also generated for most
comparisons in adults and children, but failed to reach a
statistical significance for IRP [possibly due to type II errors
(sample size) although they reached borderline significance
for ‘any pneumonia’ (all cases)]. As such, the results are
somewhat incongruent with our previous work, which
showed a 50% reduction in mortality associated with early
treatment versus none.18 It is possibly a combination of
residual confounding and misclassification of pneumonia
that has led to our current results, and it remains plausible
that these weak signals still suggest a reduction in the
occurrence of IRP.
Our other findings that NAI treatment at any time versus
no NAI, and later NAI treatment compared with no NAI,
universally increased the risks of IRP, contrast sharply with
previous observational data on hospitalised influenza
patients which found that NAI treatment (irrespective of
timing) and later antiviral therapy (initiated >48 hours after
illness onset) may improve a range of clinical outcomes.19,23–
28 Essentially similar observations were made for ‘any
pneumonia’.
Thus, in terms of the occurrence of pneumonia, our data
suggest differential effects depending on the timing and use
of NAIs; apparent harm associated with any or later NAI use
versus no NAI; but potential benefit from early NAI use
versus late NAI use or none. Based upon what is known
Table 1. (Continued)
Characteristics
Radiologically diagnosed pneumonia
status Radiologically or PDP status
IRP No IRP Any pneumonia* No pneumonia**
Ventilation support 2372 (397) 450 (134) 2619 (371) 1059 (78)
Admission to critical care 3335 (558) 764 (228) 3859 (547) 1989 (147)
Mortality 903 (151) 90 (27) 1014 (144) 496 (37)
*Any pneumonia includes influenza-related pneumonia (IRP) (n = 5978) and physician-diagnosed pneumonia (PDP) (n = 1076).
**No pneumonia includes no IRP (n = 3349), no PDP (n = 6616) and unknown pneumonia status (n = 3615).
***All percentages have been calculated using these denominators unless otherwise specified.
†Reported as clinically obese or using WHO definition for obesity (BMI ≥30 kg/m2 in adults aged ≥20 years).
††Proportions were calculated as a percentage of pregnant patients among female patients of reproductive age (13–54 years); the broader age range
was selected in preference to the WHO definition (15–44 years) after consultation with data contributors to reflect the actual fertility experience of the
sample.
†††For definition of comorbidity, see Table S3.
‡Denominators for pandemic vaccine based on patients admitted after 1 October 2009 (when vaccine potentially became available).
‡‡Percentages calculated as a proportion of the total patients in that category who received neuraminidase inhibitor (NAI) therapy.
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about the mechanism of action of NAIs,29,30 it is theoretically
possible that treatment might be ineffective [tending to
produce an odds ratio (OR) close to 1] but rather implau-
sible that it would be genuinely harmful, producing an
OR > 1 as we measured. Instead, we surmise that NAIs were
often prescribed after the development of pneumonia or
Table 2. Association between NAI treatment and pneumonia
Subgroups
Influenza-related pneumonia (IRP) Any pneumonia†
Crude OR (95% CI)
Adjusted†† OR
(95% CI)
Crude OR
(95% CI) Adjusted†† OR (95% CI)
Early NAI (≤2 days) versus no NAI treatment
Laboratory and clinically confirmed
(all ages) (n1 = 2605; n2 = 6710)
097 (077–123) 083 (064–106) 102 (087–119) 083 (070–098)*
Laboratory-confirmed cases (all ages)
(n1 = 2462; n2 = 6541)
097 (076–124) 083 (064–108) 102 (087–119) 084 (070–099)*
Adults (≥16 years) (n1 = 1934; n2 = 3897) 090 (068–117) 080 (060–106) 100 (082–123) 082 (066–102)
Children (<16 years) (n1 = 670; n2 = 2765) 104 (061–177) 076 (042–136) 089 (069–114) 078 (059–103)
Pregnant (13–54 years) (n1 = 130; n2 = 424) 088 (027–293) 096 (029–320) 094 (041–218) 067 (026–176)
Intensive care unit (ICU) patients (all ages)
Adults (≥16 years) (n1 = 583; n2 = 1015) 119 (067–213) 109 (059–202) 113 (076–167) 104 (069–156)
Children (<16 years) (n1 = 197; n2 = 447) 151 (058–397) 133 (046–378) 175 (099–312) 144 (079–262)
Early NAI (≤2 days) versus later NAI (>2 days)
Laboratory and clinically confirmed
(all ages) (n1 = 5058; n2 = 10 925)
034 (030–039)*** 043 (037–051)*** 040 (037–045)*** 051 (046–057)***
Laboratory-confirmed cases (all ages)
(n1 = 4834; n2 = 10 667)
035 (030–040)*** 044 (038–052)*** 041 (037–045)*** 052 (047–058)***
Adults (≥16 years) (n1 = 4189; n2 = 7549) 034 (029–039)*** 043 (036–051)*** 041 (036–046)*** 051 (045–058)***
Children (<16 years) (n1 = 864; n2 = 3295) 043 (029–062)*** 047 (032–071)*** 043 (035–053)*** 053 (043–066)***
Pregnant (13–54 years) (n1 = 256; n2 = 649) 026 (013–053)*** 032 (013–075)** 027 (017–044)*** 034 (020–058)***
ICU patients (all ages)
Adults (≥16 years) (n1 = 1846; n2 = 2850) 038 (029–051)*** 047 (034–063)*** 055 (045–068)*** 062 (050–077)***
Children (<16 years) (n1 = 251; n2 = 655) 046 (022–094)* 045 (020–101) 061 (042–089)** 071 (047–105)
Later (>2 days) versus no NAI treatment
Laboratory and clinically confirmed
(all ages) (n1 = 3991; n2 = 8251)
253 (202–316)*** 170 (134–217)*** 241 (209–279)*** 157 (134–184)***
Laboratory-confirmed cases
(all ages) (n1 = 3822; n2 = 8048)
251 (198–316)*** 168 (130–216)*** 238 (206–276)*** 155 (132–182)***
Adults (≥16 years) (n1 = 3263; n2 = 5572) 229 (178–295)*** 164 (125–216)*** 230 (191–277)*** 158 (129–192)***
Children (<16 years) (n1 = 724; n2 = 2598) 226 (128–399)** 168 (089–316) 199 (155–257)*** 142 (108–187)**
Pregnant (13–54 years) (n1 = 186; n2 = 383) 221 (076–645) 160 (040–649) 286 (130–625)** 158 (061–409)
ICU patients
Adults (≥16 years) (n1 = 1511; n2 = 2249) 235 (131–423)** 155 (083–289) 168 (115–246)** 147 (100–217)*
Children (<16 years) (n1 = 236; n2 = 518) 584 (150–2275)* 425 (107–1688)* 350 (190–646)*** 263 (139–496)**
NAI anytime versus no NAI treatment
Laboratory and clinically confirmed
(all ages) (n1 = 7975; n2 = 20 164)
157 (132–186)*** 132 (110–159)** 162 (145–181)*** 122 (108–138)**
Laboratory-confirmed cases
(all ages) (n1 = 7620; n2 = 19 553)
155 (129–186)*** 129 (106–157)* 158 (141–178)*** 119 (105–135)**
Adults (≥16 years) (n1 = 5964; n2 = 13 247) 153 (124–191)*** 130 (103–163)* 163 (140–189)*** 124 (106–146)**
Children (<16 years) (n1 = 2005; n2 = 6760) 138 (100–190)* 130 (092–182) 141 (118–169)*** 118 (097–143)
Pregnant (13–54 years) (n1 = 348; n2 = 1430) 148 (058–374) 103 (032–329) 174 (093–323) 108 (052–222)
ICU patients (all ages)
Adults (≥16 years) (n1 = 2721; n2 = 4071) 202 (130–314)** 157 (100–248)* 158 (114–218)** 138 (100–192)*
Children (<16 years) (n1 = 970; n2 = 1579) 145 (089–238) 139 (085–229) 176 (122–253)** 159 (110–230)*
n1 = total number of patients included in IRP analysis; n2 = total number of patients included in ‘any pneumonia’ analysis.
*P < 005, **P < 001, ***P < 0001.
†Influenza-related pneumonia and physician-diagnosed pneumonia.
††Adjusted for treatment propensity quintiles, corticosteroid use and antibiotic use.
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clinical deterioration; furthermore, patients with IRP were
admitted to hospital a median of 4 days from symptom
onset, compared to 2 days for those with no pneumonia. A
process of reverse causation is more likely to be responsible
for the elevated risk of IRP associated with any or late NAI
treatment versus none. Indeed, from our data set, we were
able to record the timing of initiation of NAI treatment in
relation to illness onset, but we lacked the ability to record
the timing of treatment in relation to the development of
pneumonia, which precluded us conducting a survival
analysis. With regard to the severity of illness at the time
of initiating NAI therapy, one functional measure would
have been to consider site of NAI treatment initiation
(outpatient, emergency department, hospital ward, ICU);
unfortunately, we were not able to do this because overall
there were too many missing data.
NAI treatment and clinical outcomes in pneumonia
Our other main finding relates to the effect of NAI treatment
on clinical outcomes in patients with IRP. Our data reveal
that patients with IRP, who were treated early with an NAI
versus later, experienced a roughly one-third lower likelihood
of dying or requiring ventilatory support. A mortality
reduction of similar magnitude was noted when comparing
early NAI versus no NAI, which was statistically significant
for the analysis of ‘any pneumonia’, but not for IRP.
Although we advise caution in the interpretation of these
subgroup analyses, essentially the same finding has been
made about ventilatory support in a very large cohort of
children hospitalised with seasonal and pandemic influen-
za.31
We also found that among patients with ‘any pneumonia’,
those who received NAIs were more likely to be managed in
an ICU or require ventilatory support compared to those not
treated with NAIs, regardless of the timing of treatment.
Confounding by indication is an important consideration in
relation to these data; that is, patients with severe pneumonia
or ARDS who were escalated to ICU-based care would be
more likely to be preferentially treated with NAIs compared
to those not requiring ICU; indeed, in the PRIDE data set
overall (n = 29 259), we noted that 82% of ICU patients
received an NAI compared with 61% in non-ICU patients
(P < 0001). The alternative explanation that NAI treatment
results in clinical deterioration with resultant increased
requirements for ICU admission or ventilatory support,
but no increase in mortality is unlikely and our results should
Table 3. Association between neuraminidase inhibitor (NAI) treatment and clinical outcomes among patients with pneumonia
Clinical outcomes/exposures studied
Influenza-related pneumonia (IRP) Any pneumonia†
Crude OR (95% CI) Adjusted†† OR (95% CI) Crude OR (95% CI) Adjusted†† OR (95% CI)
Admission to an intensive care unit
Early versus no NAI (n1 = 1480; n2 = 1855) 151 (101–225)* 144 (094–218) 202 (144–283)*** 181 (127–258)**
Early versus later NAI (n1 = 3905; n2 = 4709) 115 (094–139) 089 (071–111) 109 (092–129) 095 (079–114)
Later versus no NAI (n1 = 3255; n2 = 3864) 259 (185–361)*** 243 (171–345)*** 291 (216–391)*** 266 (195–362)***
NAI versus no NAI (n1 = 5962; n2 = 6976) 169 (130–219)*** 159 (121–209)** 196 (155–250)*** 178 (138–228)***
Ventilation support
Early versus no NAI (n1 = 1131; n2 = 1287) 112 (070–179) 117 (071–192) 124 (082–187) 113 (073–175)
Early versus later NAI (n1 = 3084; n2 = 3459) 069 (056–086)** 068 (054–085)** 074 (060–090)** 075 (061–093)**
Later versus no NAI (n1 = 2489; n2 = 2760) 231 (150–355)*** 248 (157–392)*** 218 (148–321)*** 221 (147–332)***
NAI versus no NAI (n1 = 4739; n2 = 5182) 170 (125–230)** 167 (122–229)** 169 (127–225)*** 159 (119–213)**
Acute respiratory distress syndrome
Early versus no NAI (n1 = 454; n2 = 546) 114 (032–407) 198 (046–854) 226 (076–667) 298 (077–1160)
Early versus later NAI (n1 = 1234; n2 = 1434) 054 (033–090)* 065 (038–111) 055 (037–083)** 061 (040–094)*
Later versus no NAI (n1 = 1032; n2 = 1178) 234 (098–555) 223 (090–554) 342 (150–782)** 321 (136–758)**
NAI versus no NAI (n1 = 1549; n2 = 1836) 199 (084–470) 213 (087–521) 306 (135–694)** 314 (137–729)**
Mortality
Early versus no NAI (n1 = 1490; n2 = 1866) 061 (038–096)* 072 (044–117) 059 (039–089)* 062 (040–096)*
Early versus later NAI (n1 = 3906; n2 = 4711) 084 (067–104) 070 (055–088)** 077 (063–095)* 069 (056–086)**
Later versus no NAI (n1 = 3266; n2 = 3875) 105 (073–152) 118 (081–174) 106 (076–149) 113 (080–161)
NAI versus no NAI (n1 = 5974; n2 = 7050) 088 (066–118) 090 (067–122) 089 (069–117) 089 (067–117)
n1 = total number of patients included in IRP analysis; n2 = total number of patients included in any pneumonia analysis.
*P < 005, **P < 001, ***P < 0001.
†Influenza-related pneumonia and physician-diagnosed pneumonia.
††Adjusted for treatment propensity quintiles, corticosteroid use and antibiotic use.
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not be used to justify the avoidance of early empirical use of
NAIs for patients who are severely unwell with suspected
influenza.
Technical limitations
Insufficient data on influenza vaccination limited our ability
to assess its potential effect on the clinical course of influenza
A(H1N1)pdm09 virus infection, albeit that 9890 of 20 634
patients (485%) were admitted prior to November 2009 and
could not have benefitted from H1N1pdm09 vaccine as it
would not have been available by this point.
There were wide variations across included study centres
in terms of individual study period, healthcare systems,
clinical practice, treatment policies and resource availability.
Although we attempted to control for these study-level biases
using generalised linear mixed models, residual confounding
is possible. Likewise, we cannot completely eliminate
misclassification of exposure, covariate or outcome variables.
Notwithstanding, we attempted to account for misclassifica-
tion bias by conservatively restricting our main analysis to
IRP based on chest radiograph reports. But we were unable
to discriminate between viral pneumonia, bacterial pneumo-
nia and concurrent viral and bacterial pneumonia, nor
differentiate between community- and hospital-acquired
pneumonia.
Despite requesting a minimum set of data variables
(Table S2), the nature of the surveillance data sets provided,
which were set up for monitoring during a public health
emergency, meant that there were missing data on some
variables of interest (e.g. admission diagnosis, comorbidities,
interval from the onset of symptoms to NAI treatment,
severity of disease at presentation, influenza vaccination,
concomitant therapies, complications, information on fol-
low-up).
Finally, this study does not reflect the full spectrum of
disease caused by influenza A(H1N1)pdm09 virus infection
in the community as it only examined hospitalised patients.
Implications and conclusions
Early NAI treatment probably reduces the likelihood of IRP.
We observed highly consistent protective point estimates for
early initiation of NAI treatment versus late and early
treatment versus no NAI, but only the former was statistically
significant; therefore, the evidence is strongest for an effect of
early versus later NAI treatment. Overall, NAI treatment
compared with no NAI treatment was associated with an
increased likelihood of IRP; we surmise this because NAIs are
sometimes started later in response to the development of
pneumonia.
In patients with IRP, early NAI treatment versus later
reduced the need for ventilatory support and subsequent
mortality. Because randomised controlled trials of NAI
treatment versus no NAI or placebo, or early NAI treatment
versus late, are unlikely to be ethically or practically feasible,
further evidence is needed from well-designed, prospective
cohort studies in which disease severity and the dates of
symptom onset, hospital admission, NAI treatment initiation
and pneumonia onset are all accurately and consistently
described.
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